European journal of gynaecological oncology (EUR J GYNAECOL ONCOL)

Journal description

Current impact factor: 0.61

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 0.611
2013 Impact Factor 0.602
2012 Impact Factor 0.577
2011 Impact Factor 0.474
2010 Impact Factor 0.633
2009 Impact Factor 0.614
2008 Impact Factor 0.641
2007 Impact Factor 0.587
2006 Impact Factor 0.652
2005 Impact Factor 0.591
2004 Impact Factor 0.509
2003 Impact Factor 0.547
2002 Impact Factor 0.395
2001 Impact Factor 0.562
2000 Impact Factor 0.551
1999 Impact Factor 0.397

Impact factor over time

Impact factor

Additional details

5-year impact 0.60
Cited half-life 7.30
Immediacy index 0.05
Eigenfactor 0.00
Article influence 0.14
Website European Journal of Gynaecological Oncology website
Other titles European journal of gynaecological oncology
ISSN 0392-2936
OCLC 7236962
Material type Periodical
Document type Journal / Magazine / Newspaper

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: The studies for the prevention of uterine cervical cancer in Panama City began in a private institute, impelled by the high incidence of cancer. The preventive programs were initiated with the support of the Obstetrics and Gynecology Institute of the University of Padua in Italy. In these studies, we applied the methodological diagnostics of this Institute with certain modifications adapted to our needs. The diagnosis, treatment, and follow-up were carried out under the protocol of the University of Padua. We achieved a diagnosis of oncogenic risk (OR) in 6,411 patients which corresponded to 5,498 cases of human papillomavirus (HPV), 1,150 cases of dysplasia, 210 cases of cancer, and 794 cases of OR. From 2011, polymerase chain reaction (PCR) was also applied with the aim to improve the accuracy of the diagnosis. With this method the prevalence of pathologies were HPV infections both in healthy patients or in patients cured from HPV. Patients were treated by means of local destructive treatments (LDT), basically with cryotherapy and cauterization. We can consider these results as successful prevention and suggest to extend a preventive program to all the population.
    European journal of gynaecological oncology 07/2015; 36(3):252-4.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the correlation between transcription factor activator protein-2β (TFAP-2β) and endometrial carcinoma (EC). The study comprised 60 randomly selected patients diagnosed and treated at the 2nd Affiliated Hospital of Harbin Medical University from November 2011 to June 2012 for endometrial carcinoma (n = 30) and myoma of uterus (n = 30). The expression of TFAP-2Pβ mRNA in endometrial carcinoma was analyzed by real-time reverse transcription polymerase chain reaction (RT-PCR). Body mass index (BMI), waist circumference, and venous blood samples were obtained before abdominal surgery clinically. The expression of TFAP-2β mRNA in endometrial tissue of patients with EC was higher than that of normal endometrium (p < 0.05). The expression of TFAP-2β mRNA in endometrial tissue of patients with metabolism syndrome was higher than that of lean ones (p < 0.05). There was no significant difference in the expression of TFAP-2β mRNA in endometrial tissue between patients with both EC and metabolism syndrome and in those with EC only. The expression levels of TFAP-2β mRNA had positive correlation with triglyceride (r = 0.271, p < 0.05) and high-density lipoprotein (HDL) (r = 0.314, p < 0.05). There was no significant correlation between the expression of TFAP-2β mRNA and CA125, fasting plasma glucose, low-density lipoprotein (LDL), waist circumference, total cholesterol, and BMI. TFAP-2β constituted promoter activity in EC and also contributed to the development of the metabolic syndrome. TFAP-2β may influence the oc- currence and development of EC through regulating the expression of various adipokines and lipoprotein metabolism. Probably TFAP-2β can be a candidate tumor marker for EC.
    European journal of gynaecological oncology 07/2015; 36(3):268-73. DOI:10.12892/ejgo2609.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Revised manuscript accepted for publication March 5, Objectives: The purpose of this study was to determine the potential of cancer testis antigen OY-TES-1 as a vaccine for ovarian cancer (OC). A tissue microarray (TMA) containing 107 samples from OC tissues and 48 samples from OC adjacent tissues was analyzed by immunohistochemistry with the OY-TES-1 polyclonal antibody. The correlation between OY-TES-1 and clinic pathological traits of OC was statistically analyzed. The expression of OY-TES-1 protein was found in 81% (87/107) of OC tissues and 56% (27/48) of OC adjacent tissues. The immunostaining intensity of OY-TES-1 in OC tissues was significantly higher than that in OC adjacent tissues tested (p = 0.040). OC adjacent tissues only demonstrated lower immunostaining intensity, whereas some of OC tissues presented higher immunostaining intensity and majority showed the heterogeneity of protein distribution. There was no statistically significant correlation found between OY-TES-1 expression and any other clinicopathological traits such as age, FIGO stage, pathological grade, and histological type. OY-TES-1 was expressed in OC tissues with a high proportion, and some of OC tissues presented OY-TES-1 expression in high level vs OC adjacent tissues. OY-TES-1 could be an attractive target for immunotherapy for OC in the future.
    European journal of gynaecological oncology 07/2015; 36(3):298-303. DOI:10.12892/ejgo2636.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To determine the efficacy and toxicity of a combined-modality regimen of neoadjuvant chemotherapy (NACT) before primary radical surgery followed by adjuvant chemoradiation in small cell neuroendocrine cervical cancer (SCNEC) patients. The study was approved by the ethics committee of the present hospital. The records of 23 SCNEC patients who received NACT before primary radical surgery were reviewed at the Zhejiang Cancer Hospital between January 1998 and May 2010. All patients received one to four cycles of NACT and two to eight cycles of chemotherapy (NACT and adjuvant chemotherapy) on the basis of platinum, 17 (73.9%) patients received NACT using a regimen consisting of etoposide and cisplatin (EP). Eighteen (85.7%) patients received adjuvant chemotherapy using a regimen consisting of PE and EP. Kaplan-Meier and Cox regression methods were used for analyses. Of the 23 eligible patients, 18 had Stages I-IIA, five had Stages IIB-IIIB disease. Twelve patients (52.2%) developed grade 3 and 4 neutropenia. Fourteen patients (60.9%) developed grade 3 and 4 anemia. The majority of grade 3 and 4 neutropenia and non-hematologic toxicities were usually self-limited. Three patients (13.0%) who postoperative pathology showed pathologic complete response (CR) had better prognosis than those did not show pathologic CR; the median survival was 69.5 months (range, 51.1-177.1), 54.5 months (range: 7.3-81.5), respectively. In univariate analysis, lymphovascular space invasion (LSI) (p = 0.013), and deep stromal invasion (DSI) (p = 0.001) were considered poor prognostic factors. With a median follow-up for surviving patients was 40.8 months (range, 7-177), 12 patients recurred, 11 of which had died. The estimated three- and five-year overall survival (OS) rates for all patients were 55.8% and 39.9%, respectively. NACT before primary radical surgery followed by adjuvant chemoradiation or chemotherapy was well tolerated and seems to be effective for early stage SCNEC patients. Prospective clinical study is necessary and we hope that this research's results help to design a prospective clinical study.
    European journal of gynaecological oncology 07/2015; 36(3):326-9. DOI:10.12892/cjgo2723.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose of investigation: Ovarian cancer is associated with poor prognosis and altered protein expression patterns may be useful for identifying patients likely to have poor disease outcomes. The impact of altered INPP4B protein expression on prognosis is unclear. The aim of this study was to evaluate the implication of INPP4B expression changes in a large series of ovarian cancer tissue samples. Materials and methods: Tissue microarrays were constructed from 599 epithelial ovarian tumors and stained with antibodies for INPP4B, p53, and PTEN. Proportional hazard models were used to estimate survival hazard ratios (HRs) associated with altered protein expression. Results: Seventy-nine percent of the ovarian cancers demonstrated loss of INPP4B, whereas 53% showed aberrant p53 expression (i.e., complete loss of p53 or over-expression of p53) and 8% showed loss of PTEN. INPP4B was frequently lost in serous and endometrioid cancer subtypes, aberrant p53 expression was most common among serous subtype, and loss of PTEN was most common among endometrioid tumors (p for all three proteins across histologic subtypes ≤ 0.0001). INPP4B loss or aberrant p53 expression were both associated with increased mortality (HR = 1.84; 95% CI 1.27 - 2.68 and HR = 3.10; 95% CI 2.33 - 4.11, respectively); however, in multivariate models, only the relationship with p53 achieved statistical significance (HR = 1.20; 95% CI 0.82 - 1.76 for INPP4B and HR = 1.73; 95% CI 1.28 - 2.34 for p53). Conclusion: The INPP4B protein is frequently lost in serous and endometrioid subtypes of ovarian cancer. A possible prognostic role of INPP4B for endometrioid ovarian tumors requires further evaluation.
    European journal of gynaecological oncology 07/2015; 36(3):260-7. DOI:10.12892/ejgo2741.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to discuss the differences of malignant findings in breast lesions diagnosed with Breast Imaging-Reporting and Data System for Ultrasonography (BI-RADS-US) category 4C to determine which malignant findings are more important. A total of 159 cases of breast lesions diagnosed with BI-RADS-US category 4C were analyzed retrospectively. All patients got pathological results (81 cases of benign; 78 cases of breast cancer). Two doctors scanned and diagnosed the patients, with another doctor recording ultrasonographic findings retrospectively. The differences were compared by means of the Chi-square (χ2) test. Phyllodes and acoustic attenuation had statistical differences in the comparison of breast lesions (p < 0.05). Irregular shape, indistinct boundary, poorly-defined margin, penetrating or tortuous surrounding vessels, RI ≥ 0.7, and microcalcification had no statistical differences in the comparison of benign and malignant breast lesions. Phyllodes and acoustic attenuation are the more important malignant ultrasonographic findings of breast cancer. The malignant ultrasonographic findings are not unique for breast cancer.
    European journal of gynaecological oncology 07/2015; 36(3):294-7. DOI:10.12892/ejgo2635.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To compare the ability of cytology, human papillomavirus (HPV) testing and co-testing to identify recurrence of patients treated by loop electrosurgical excision procedure (LEEP) for cervical intraepithelial neoplasia (CIN) 2-3. Retrospective analysis (R.A.): the medical records of 372 women treated for CIN 2-3 were reviewed. Resection margin, HPV typing, Pap smears, and biopsies post-LEEP were collected. Prospective analysis (P.A.): 97 women were followed post-LEEP by cytology, HPV test and colposcopy every six months. Positive margins were found to be an independent risk factor for recurrent disease (OR 0.192; 95% CI 0.074-0.497 in R.A. and OR 0.096; 95% CI 0.023-0.392 in P.A.). HPV testing showed less sensitivity than cytology (69% vs 84%, respectively in R.A. and 80% vs 100% in P.A.). Co-testing predicted recurrent disease at a sensitivity of 90.6% in R.A. and 100% in P.A. Co-testing is the best option in follow-up protocols after treatment for CIN 2-3. If margins are free and co-testing is negative at six and 12 months, 18 months visit could be avoided.
    European journal of gynaecological oncology 07/2015; 36(3):245-51. DOI:10.12892/ejgo2633.2015
  • C Yu · W Zhu · Y Ji · J Guo · P Pan · J Han · X Zhou
    [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to compare three-dimensional conformal radiotherapy (3D CRT) and intensity-modulated radiotherapy (IMRT) combined with concurrent chemotherapy for cervical cancer. A total of 72 patients with Grades IIa-IIIb cervical cancer were randomly divided into two groups, namely, the IMRT group for IMRT plan (primary lesion, 45 Gy/22; the pelvic wall lymphatic drainage area, 50 Gy/22), and the 3D CRT group (conformal pelvic radiotherapy, 45 Gy/22; subsequent supplement of pelvic wall, 6.0 Gy/3). Both groups received concurrent chemotherapy of nedaplatin 30 mg/m2 weekly for six cycles, with an after-loading therapy of 6 Gy/6 each time. In the IMRT group, the grade III diarrhea rate was 5.6% and the rate in the 3D CRT group was 30.6%; both groups significantly differed. No significant difference was observed between the overall survival and disease-free survival in first, second, and third years in both groups. Cervical cancer IMRT can significantly reduce the incidence of acute enteritis. For standard 3D CRT, no significant difference was observed in overall survival and disease-free survival.
    European journal of gynaecological oncology 07/2015; 36(3):278-82. DOI:10.12892/ejgo2622.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: This paper presents a case of carcinosarcoma localized in the endometrial polyp inside the uterus of a 74-year-old patient. This carcinosarcoma was diagnosed in the first clinical disease stage. Postoperative treatment was conducted but was not followed by additional chemo or radiotherapy due to the fact that the illness was in the first clinical stage. Secondary deposits in the abdomen and in the pelvis appeared exactly six months after surgery. Illness progression was sudden causing death three months after the appearance of secondary deposits or nine months after the illness was detected, despite attempts with chemotherapic treatment. Although uterine carcinosarcomas account for three to seven percent of all uterine malignities while malignant polyp degeneration occurs in only 0.36% cases, treatment of this malignant disease is a special challenge to all those involved in oncological gynecological practice with the aim of prolonging the progression-free interval and the overall survival of patients suffering from this rare malignity.
    European journal of gynaecological oncology 07/2015; 36(3):346-7.
  • [Show abstract] [Hide abstract]
    ABSTRACT: This study aimed to determine whether phosphorylation of histone H2AX (γH2AX) is a predictive marker for neoadjuvant chemotherapy patients of cervical cancer. The sections were divided into three sets. Set 1 consisted of 40 pre-treatment biopsies. Post-treatment tissues includes 38 patients in set 2 and 34 patients in set 3 who received cisplatin concurrent docetaxel treatment for one or two cycles, respectively. Formalin-fixed paraffin-embedded sections were analyzed after antigen retrieval and fluorescence antibody labeling for γH2AX staining. The expressions of γH2AX in cervical cancer tissues of post-neoadjuvant chemotherapy decreased to 22.94 ± 14.02% and 23.68 ± 13.55% (one and two cycles treatment, respectively) compared to preneoadjuvant chemotherapy (28.29 ± 15.67%), however there was no significant difference for γH2AX expression between pre- and post-neoadjuvant chemotherapy patients (F = 1.425, p = 0.245). There was no significant correlation between γH2AX expression and clinicopathologic parameters in patients of pre- and post-neoadjuvant chemotherapy. As a predictive marker for neoadjuvant chemotherapy of cervical cancer, more extensive research regarding γH2AX expression should be explored.
    European journal of gynaecological oncology 07/2015; 36(3):318-22. DOI:10.12892/ejgo2689.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cervical cancer case supervened with chylous ascites after extensive hysterectomy is rarely reported, and is very difficult to deal with. A 40-year-old female patient complained of a small amount of vaginal bleeding after intercourse over the past seven years, and then was diagnosed as cervical squamous cell carcinoma IIa, with moderate anemia and leucopenia. The patient underwent radiotherapy and was given leucogen and iron dextran to elevate blood leukocyte at the same time. Considering blood routine examination was normal, the patient underwent extensive hysterectomy, bilateral adenectomy, and pelvic lymphadenectomy. By day 30 postoperatively, chyluria test showed positive which indicated chylous ascites in the patient. Since then, the patient successively had hypoproteinemia, electrolyte imbalance, high fever, fungal infection, etc. Very fortunately, the patient made a remarkable recovery from the serious condition after a series of flexible anti-infection and effective supportive treatments. Chylous ascites leads to the loss of lipid, plasma protein, fat-soluble vitamins, and subsequently malnutrition. Firstly, the primary disease should be dealt with through chemotherapy or radiotherapy for malignant tumors. Anti-infective therapy can prevent intra-abdominal infections and the occurrence of bacteremia. Considering postoperative treatments last longer in this case, the authors changed antibiotics several times to avoid drug resistance. However, the patient unfortunately had complication of fungal septicemia due to the serious condition, which should to be avoided next time. In addition, the balance of water, electrolyte, and acid-base is particularly important in the overall treatment.
    European journal of gynaecological oncology 07/2015; 36(3):356-8.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Ovarian malignant tumours are mostly ovarian cancers. The most frequent ovarian benign lesions are mature teratomas. A very rare ovarian neoplasm is carcinoid. It mostly occurs as a component of mature teratoma, what causes rare diagnosis before surgery. Study presents the case of patient with primary ovarian carcinoid in mature teratoma of one ovary, co-existing with primary epithelial carcinoma of another ovary. Surgical treatment of carcinoid involves adnexectomy or hysterectomy with adnexa and removal of great omenturn, followed by chemotherapy and radiotherapy. In young women with early-stage tumours, treatment can be limited to adnexectomy followed by close monitoring. In the presented case, management associated with the diagnosis of ovarian carcinoid, resulted in the detection of early-stage ovarian epithelial cancer. This case seems to confirm the recommendations to take tissue samples from the other ovary for histopathological evaluation in cases of ovarian unilateral benign tumours.
    European journal of gynaecological oncology 07/2015; 36(3):330-2.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate mRNA expression profiles associated with cervical squamous carcinoma progression and to identify key genes involved in invasion and metastasis of cervical squamous cancer. The authors extracted the mRNA expression profile of eight normal cervical tissues by human whole genome microarray. The main functions of differentially expressed genes were identified by gene ontology (GO) analysis. Gene-networks were established based on bioinformatic approaches. Microarray data of the expressions level of key genes verified by qRT-PCR. The authors identified 2036 differentially expressed genes between two groups including 1,282 down-regulated genes and 754 up-regulated genes (p < 0.05, FDR < 0.05). Gene-network revealed that PDGFRA, CAV1, and GJA-1 were critical for cervical cancer invasion and metastasis. PDGFRA, CAV1, and GJA-1 were revealed as key node genes for cervical cancer invasion and metastasis. The results may provide new evidences and ideas for early diagnosis and prognosis assessment of cervical cancer.
    European journal of gynaecological oncology 07/2015; 36(3):309-17. DOI:10.12892/ejgo2683.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Nowadays complete primary cytoreduction can be achieved in a large number of patients suffering from advanced ovarian cancer. However, there is a group of patients in whom complete tumor resection remains impossible. The authors analyzed the intraoperative limiting factors in patients with residual tumor after primary surgery treated in the present institution. Patients with advanced epithelial ovarian cancer (FIGO Stage IIIB-IV), who underwent primary incomplete surgery in the present institution between 2006 and 2008 were included in this study. Patients' records were evaluated regarding to intraoperative findings and final surgical results. The authors identified 39 eligible patients in their registry. Twenty-six (66.7%) patients underwent surgery with residual tumor < 1 cm and 13 (33.3%) ≥ 1 cm. The most frequent location of residual tumor limiting complete surgery was disseminated bowel carcinomatosis in 34 (87.2%) patients. Moreover significant differences in tumor residuals locations and operative time between patients with residuals < 1 cm and ≥ 1 cm were reported (p < 0.05). The most frequent reason for incomplete primary cytoreduction remains disseminated carcinomatosis. However, in patients with residuals under one cm, its frequency is significantly higher. The complication rate is comparable in patients independently of residual tumor < 1 cm and ≥ 1 cm. Therefore the cytoreductive efforts should be made even in primarily not completely operated patients in order to achieve residuals under one cm.
    European journal of gynaecological oncology 07/2015; 36(3):274-7. DOI:10.12892/ejgo2794.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Endometrial carcinoma is the most common invasive neoplasm of the female genital tract and is associated to the elevated levels of unopposed estrogen, especially in postmenopause. Ovarian Steroid cell tumors are rare tumors and they are named according to the origin of cell. The most common cancer of the female genital tract is the endometrial adenocarcinoma and it accounts for 7% of all invasive cancers in women. In the present case report, the authors present a 59-year-old multiparous woman with a postmenopausal bleeding complaint and they discuss the case of ovarian steroid cell tumor associated with endometrioid adenocarcinoma of endometrium. Endometrial adenocarcinoma is the most common cancer of female genital tract and its contemporarity with an ovarian steroid cell tumor is extremely rare.
    European journal of gynaecological oncology 07/2015; 36(3):348-50.
  • [Show abstract] [Hide abstract]
    ABSTRACT: The effectiveness of local destructive treatments (LDT) applied in patients due to cervical pathology oncogenic risk (OR), were followed and verified in 396 patients who came to our attention, focusing on the type of pathology, type of treatment received, diagnosis clinical evolutionary, and results of the new study applying polymerase chain reaction (PCR), and above all, the time between the diagnosis, treatment, and PCR findings. The clinical evolution of the same reports achieved a healing rate of 82% followed by persistence 8.3%; improvement 4.8%, recurrence 2.8%, and only one case of progression 0.2%. The elapsed time in initial care and treatment was almost immediate, as the pathology diagnosis was considered on an emergency basis. Successive controls of these indicated that 119 studies of routine colposcopy were carried out, on an average of the first three years and with a maximum follow up of 30 years, with over 30 routine colposcopies that achieved healing in most of these. In 2011 and 2012, we added to the usual diagnostic methodology, molecular biology, and 119 studies were performed in those patients, resulting in only five negative cases. Most studies were classified as high risk papillomavirus (HR-HPV), corresponding to subtypes 31, 35, 18, and 16.
    European journal of gynaecological oncology 07/2015; 36(3):323-5.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Primary vaginal leiomyosarcoma in pregnancy is an extremely rare disease which continues to have a poor prognosis. This is due to the late diagnosis as well as the treatment is based on limited experience based on case reports and not randomised trials. The authors report the first case of leiomyosarcoma of the vagina in a pregnancy in a 31-year-old Afro-Caribbean multigravida at the Mt. Hope Maternity Hospital. Despite the administration of systemic chemotherapy and irradiation, the patient succumbed to her illness 11 months after the initial diagnosis. If the prognosis is to be improved, it is prudent that healthcare providers must be more aware and knowledgeable of this tumour and be proactive in its management.
    European journal of gynaecological oncology 07/2015; 36(3):339-40.
  • [Show abstract] [Hide abstract]
    ABSTRACT: To report and explore the effectiveness of the endoscopic surgery combining cisplatin, etoposide, and bleomycin (PEB) chemotherapy in treating vaginal yolk-sac tumor. The clinical case of vaginal yolk-sac tumor in a young girl was analyzed. Hysteroscopy equipment was used to inspect and remove the majority of the tumor tissue, followed by six cycles of PEB chemotherapy. Hysteroscopy equipment was used again to exam the vagina and remove of the tumor pedicle for biopsy, which revealed no tumor cells after two cycles of chemotherapy. The patient remained disease free on follow up for a year. The use hysteroscopy equipment to exam vagina can diagnose early vaginal yolk-sac tumor and cytoreductive surgery which can preserve fertility can then be performed. Cytoreductive surgery may also be able to reduce the cycles of the chemotherapy to reduce the side effects and the risks of chemotherapy.
    European journal of gynaecological oncology 07/2015; 36(3):335-8. DOI:10.12892/ejgo2658.2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: To investigate the potential relevance of c-Met and RON gene expression in patients with adenocarcinoma of the endometrium and analyze the relationships among the c-Met and RON expression, clinicopathological characteristics, and patient survival. The study included 60 cases diagnosed with endometrial adenocarcinoma with more than five-years follow-up. Total RNA from formalin-fixed paraffin-embedded tissues of 60 adenocarcinomas of the endometrium and normal endometrium tissues were isolated for c-Met and RON quantitative analysis by real-time real-time polymerase chain reaction (RT-PCR). The c-Met and RON expression in endometrial adenocarcinoma was significantly higher than that in normal endometrial tissues (p < 0.01), with average up-regulated levels of 3.94 ± 1.88 and 2.74 ± 0.88, respectively. Moreover, high c-Met expression was significantly correlated with the histological stage (p = 0.017), and high RON expression was related to histological stage (p = 0.035), muscle invasion (p = 0.006), and lymph node metastasis (p = 0.018). Multivariate Cox regression analysis revealed that the co-expression of c-Met and RON was an independent prognostic factor for adenocarcinoma of the endometrium and was significantly associated with decreased overall survival (HR = 3.571, p = 0.014). The co-expression of c-Met and RON is associated with a poor prognosis in endometrial adenocarcinoma and is an independent prognostic marker for endometrioid adenocarcinoma.
    European journal of gynaecological oncology 07/2015; 36(3):255-9. DOI:10.12892/ejgo2575.2015